The case for & against
Bull & Bear analysis
Medtronic plc (NYSE: MDT) is a global leader in medical technology, specializing in a wide array of medical devices and therapies aimed at managing chronic conditions across various therapeutic areas, including cardiovascular, diabetes care, and neurological disorders. Positioned prominently within the MedTech industry, Medtronic seeks to enhance patient outcomes through innovative technological solutions, such as the recently launched AltaViva for treating urinary incontinence, which demonstrates its commitment to patient-driven healthcare advancements. The company's strategic focus on addressing chronic diseases and the ongoing pursuit of operational efficiencies amplify its competitive advantages in a challenging healthcare environment.
Bull says
- ↑Q4 FY26 revenue of $9.8B (+9.9% YoY); FY27 organic growth guided at 6.75–7.25%.
- ↑CAS segment revenue up 78% YoY aided by strong procedural demand.
- ↑R&D spend up 7.7% supports pipeline innovations like AltaViva and PFA.
- ↑Management targets high single-digit EPS growth; FY27 EPS guidance $5.90–$6.00.
- ↑Dividend yield ~1.18% and book-to-price ~0.51 indicate yield and undervaluation.
- ↑Positive momentum factors and analyst ‘Moderate Buy’ consensus bolster outlook.
Bear says
- ↓Weak profitability with low margins and poor returns on revenue.
- ↓Recent breach exposed data of 3.8M individuals, raising regulatory risks.
- ↓Elevated short interest highlights negative sentiment and potential stock volatility.
- ↓Execution risks for Simplicity and AltaViva launches amid tariff headwinds.
- ↓Intense competition in cardiovascular devices could erode CAS market share.
- ↓Analyst downgrades and weakening growth indicators heighten downside concerns.
Investment themes with MDT
Companies paying above-average dividends
Services and products for aging population
Earnings Call · Q4 2025 · Mgmt. Guidance
Transcript signals
Bull points
- we had a strong finish to our fiscal year, growing 5.4%. Our growth drivers are having an impact and are still building momentum.
- Our cardiovascular growth accelerated, as forecasted, growing 8% on broad strength across the portfolio, including nearly 30% growth in CAS.
- We also delivered double-digit growth in neuromodulation and diabetes and high single-digit U.S. growth in cranial and spinal technologies.
Bear points
- And finally, our EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year.
- our adjusted gross margin was 65.1%, down 70 basis points year over year as a result of mix from diabetes and CAS, as well as foreign exchange.
- our adjusted tax rate of 16% was better than expected due to favorability in our actual jurisdictional mix of profits for the year, which also resulted in a modest pickup from prior quarters.